Loading...
Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
Nakhoda, Shazia Rizwan, Farsha Vistarop, Aldana Nejati, Reza
Nakhoda, Shazia
Rizwan, Farsha
Vistarop, Aldana
Nejati, Reza
Citations
Altmetric:
Genre
Journal article
Date
2022-06-14
Advisor
Committee member
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.3390/cancers14122936
Abstract
Classical Hodgkin’s lymphoma is a highly curable disease, but 10–25% of patients with higher-risk disease relapse. The introduction of checkpoint inhibitors (CPIs) targeting PD-1 have changed the landscape of treatment for patients with relapsed/refractory disease to multiple lines of therapy. The depth of response to CPI as a monotherapy is highest in the first relapse as salvage therapy based on outcomes reported in several phase II studies. With earlier use of CPI and brentuximab vedotin, the optimal sequencing of therapy is evolving. In this review, we will summarize clinical investigation of anti-PD-1 mAb in earlier line settings to provide insights on utilizing these agents as chemotherapy- and radiation-sparing approaches, increasing depth of response, and as part of combination regimens.
Description
Citation
Nakhoda, S.; Rizwan, F.; Vistarop, A.; Nejati, R. Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma. Cancers 2022, 14, 2936. https://doi.org/10.3390/cancers14122936
Citation to related work
MDPI
Has part
Cancers, Vol. 14, Iss. 12
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu